# US 2026/0035382 A1 · Compounds as sumo activating enzyme inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0035382 A1
- Document ID: US20260035382A1
- Status: Published application
- Kind: A1
- Application number: 19/101,423
- Filed: 2023-09-27
- Published: 2026-02-05
- Earliest claimed: 2022-09-30
- Assignees: Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- Applicants: Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- Inventors: Yuli XIE; Yingming WU; Lihui QIAN
- Web page: https://patentgrep.com/patent/US20260035382A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07D 495/10: Spiro-condensed systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- C07B 59/002: {Heterocyclic compounds}
- C07D 495/20: Spiro-condensed systems
- C07D 495/22: in which the condensed system contains four or more hetero rings
- C07D 513/10: Spiro-condensed systems
- C07D 513/20: Spiro-condensed systems
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Disclosed in the present disclosure are compounds as SUMO activating enzyme inhibitors. Specifically, the present disclosure relates to a compound of general formula (1), a method for preparing same, and use of the compound of general formula (1) and isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates thereof as SAE inhibitors. The compound and the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof of the present disclosure can be used in preparing a medicament for treating or preventing a disease related to SAE protein.

## Claims

### Claim 1

A compound of general formula (1) or an isomer thereof, a crystalline form thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof:
wherein in general formula (1):
Y is —O—, —CH2—, or —N(H)—;
Ra is —H, —F, —NH2, or —OH;
Ra′ is —H or —F, and when Ra is —NH2 or —OH, Ra′ is —H;
Rb is —H or (C1-C4) alkyl;
Rc is —H or (C1-C4) alkyl;
Rd is —H, halogen, —CF3, or (C1-C4) alkyl;
X1 is C(H), C(F), or N;
X2 is S or O;
X3 is C(Rx3) or N;
Rx3 is —H, halogen, or —CH3;
X4 is S, O, C(Rx41)(Rx41′), or N(Rx42);
Rx42 is —H, (C1-C4) alkyl or (C3-C5) cycloalkyl;
Rx41 and Rx41′ are each independently and optionally —H, halogen, —OH, —ORx411, N(Rx411)(Rx412), —CN, (C1-C6) alkyl, (C1-C6) haloalkyl, (C3-C9) cycloalkyl, or (C1-C6) alkoxy;
Rx411 and Rx412 are each independently and optionally —H, (C1-C4) alkyl, or (C3-C5) cycloalkyl, or Rx411 and Rx412 on a same nitrogen atom, together with the N atom to which they are attached, can form (3- to 6-membered) heterocycloalkyl, wherein the (3- to 6-membered) heterocycloalkyl may be optionally substituted with 1, 2, 3, or 4 of the following groups: —H or halogen;
R3 and R4 are each independently and optionally —H, -D, —OH, —NH2, —CN, (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C9) cycloalkyl, (C1-C6) alkoxy, (C6-C14) aryl, (3- to 11-membered) heterocycloalkyl, or (5- to 11-membered) heteroaryl, wherein the (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C9) cycloalkyl, (C1-C6) alkoxy, (C6-C14) aryl, (3- to 11-membered) heterocycloalkyl, or (5- to 11-membered) heteroaryl may be each independently and optionally substituted with 1, 2, 3, or 4 of the following groups: —H, halogen, —OH, —(CH2)rOR31, —(CH2)rNR31R32, —OR31, —NR31R32, —CN, —C(O)NR31R32, —NR32C(O)R31, —NR32S(O)2R31, —S(O)pR31, and —S(O)2NR31R32; or R3 and R4, together with the carbon atom to which they are attached, can form a (4- to 7-membered) heterocycloalkyl or (C3-C6) cycloalkyl, wherein the (4- to 7-membered) heterocycloalkyl or (C3-C6) cycloalkyl may be optionally substituted with 1, 2, 3, or 4 of the following groups: —H, halogen, (C1-C6) alkyl, or (C1-C6) alkoxy; or R3 and the adjacent R5, together with the atoms to which they are attached, can form a (C3-C9) cycloalkyl or (3- to 11-membered) heterocycloalkyl, wherein the (C3-C9) cycloalkyl or (3- to 11-membered) heterocycloalkyl may be each independently and optionally substituted with 1, 2, 3, or 4 of the following groups: —H, halogen, (C1-C6) alkyl, or (C1-C6) alkoxy; or when R3 and the adjacent R5 are both absent, an endocyclic double bond is formed; or
R3 and R4 together form an oxo;
R5 and R6 are each independently and optionally —H, -D, —OH, —NH2, —CN, (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C9) cycloalkyl, (C1-C6) alkoxy, (C6-C14) aryl, (3- to 11-membered) heterocycloalkyl, or (5- to 11-membered) heteroaryl, wherein the (C1-C6) alkyl, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C9) cycloalkyl, (C1-C6) alkoxy, (C6-C14) aryl, (3- to 11-membered) heterocycloalkyl, or (5- to 11-membered) heteroaryl may be each independently and optionally substituted with 1, 2, 3, or 4 of the following groups: —H, halogen, —OH, —(CH2)rOR31, —(CH2)rNR31R32, OR31, —NR31R32, —CN, —C(O)NR31R32, —NR32C(O)R31, —NR32S(O)2R31, —S(O)pR31, and —S(O)2NR31R32; or R5 and R6, together with the carbon atom to which they are attached, can form a (4- to 7-membered) heterocycloalkyl or (C3-C6) cycloalkyl, wherein the (4- to 7-membered) heterocycloalkyl or (C3-C6) cycloalkyl may be optionally substituted with 1, 2, 3, or 4 of the following groups: —H, halogen, (C1-C6) alkyl, and (C1-C6) alkoxy; or R5 and R6 together form an oxo;
ring A is (C6-C10) aryl or (5- to 10-membered) heteroaryl;
each R1 is independently and optionally: —H, halogen, —OH, —NO2, —NR31R32, —(CH2)rOR31, —(CH2)rNR31R32, —CN, (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C8) cycloalkyl, —C(O)NR31R32, —NR32C(O)R31, —NR32S(O)2R31, —S(O)pR31, or —S(O)2NR31R32, wherein the (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, (C2-C6) alkenyl, (C2-C6) alkynyl, or (C3-C8) cycloalkyl may be each independently and optionally substituted with 1, 2, 3, or 4 of the following groups: —H, halogen, —OH, —(CH2)rOR31, —(CH2)rNR31R32, —OR31, —NR31R32, —CN, and (C1-C6) alkyl;
ring B is (C5-C7) cycloalkyl or (5- to 7-membered) heterocycloalkyl;
each R2 is independently and optionally: —H, halogen, —OH, —NR31R32, —CN, (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) alkoxy, (C2-C6) alkenyl, (C2-C6) alkynyl, or (C3-C8) cycloalkyl; or two R2 on a same carbon atom, together with the carbon atom to which they are attached, can form (4- to 6-membered) heterocycloalkyl or (C3-C6) cycloalkyl, wherein the (4- to 6-membered) heterocycloalkyl or (C3-C6) cycloalkyl may be optionally substituted with 1, 2, 3, or 4 of the following groups: —H, halogen, (C1-C6) alkyl, and (C1-C6) alkoxy; or two R2 on a same carbon atom together form an oxo;
R31 and R32 are each independently and optionally —H, (C1-C4) alkyl, or (C3-C5) cycloalkyl, or
R31 and R32 on a same nitrogen atom, together with the N atom to which they are attached, can form (3- to 6-membered) heterocycloalkyl, wherein the (3- to 6-membered) heterocycloalkyl may be optionally substituted with 1, 2, 3, or 4 of the following groups: —H and halogen; and
n is an integer selected from 0, 1, 2, 3, or 4, m is an integer selected from 0, 1, 2, 3, or 4, r is an integer selected from 0, 1, or 2, and p is an integer selected from 0, 1, or 2.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), Rd is —H, —F, —CF3, or —CH3, and Rx42 is —H, (C1-C3) alkyl, or (C3-C5) cycloalkyl.

### Claim 4 (depends on 3)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 3 wherein in the general formula (1), Rx42 is —H,

### Claim 5 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), Rx41 and Rx41′ are each independently and optionally —H, —F, —OH, —OCH3, —N(CH3)2, —NH2, —CN,
—CF3, —CH2CF3,

### Claim 6 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), R3 and R4 are each independently and optionally —H, -D, —OH, —NH2, —CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C5) cycloalkyl, (C1-C3) alkoxy, phenyl, (4- to 6-membered) heterocycloalkyl, or (5- to 6-membered) heteroaryl, wherein the (C1-C3) alkyl, (C1-C3) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C5) cycloalkyl, (C1-C3) alkoxy, phenyl, (4- to 6-membered) heterocycloalkyl, or (5- to 6-membered) heteroaryl may be each independently and optionally substituted with 1, 2, 3, or 4 of the following groups: —H, —F, —OH, —CH2OCH3, —CH2N(CH3)2, —OCH3, —N(CH3)2, —CN, —C(O)N(CH3)2, —NCH3C(O)CH3, —NHC(O)CH3, —NCH3S(O)2CH3, —NHS(O)2CH3, —SCH3, —S(O)2CH3, —S(O)2NH2, and —S(O)2N(CH3)2; or R3 and R4, together with the carbon atom to which they are attached, can form (4- to 6-membered) heterocycloalkyl or (C3-C4) cycloalkyl, wherein the (4- to 6-membered) heterocycloalkyl or (C3-C4) cycloalkyl may be optionally substituted with 1, 2, 3, or 4 of the following groups: —H, —F,
or —OCH3; or R3 and the adjacent R5, together with the atoms to which they are attached, can form a (C3-C6) cycloalkyl or (3- to 6-membered) heterocycloalkyl, wherein the (C3-C6) cycloalkyl or (3- to 6-membered) heterocycloalkyl may be each independently and optionally substituted with 1, 2, 3, or 4 of the following groups: —H, —F,
or —OCH3; or when R3 and the adjacent R5 are both absent, an endocyclic double bond is formed; or R3 and R4 together form an oxo.

### Claim 7 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), R5 and R6 are each independently and optionally —H, -D, —OH, —NH2, —CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C5) cycloalkyl, (C1-C3) alkoxy, phenyl, (4- to 6-membered) heterocycloalkyl, or (5- to 6-membered) heteroaryl, wherein the (C1-C3) alkyl, (C1-C3) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C5) cycloalkyl, (C1-C3) alkoxy, phenyl, (4- to 6-membered) heterocycloalkyl, or (5- to 6-membered) heteroaryl may be each independently and optionally substituted with 1, 2, 3, or 4 of the following groups: —H, —F, —OH, —CH2OCH3, —CH2N(CH3)2, —OCH3, —N(CH3)2, —NH2, —CN, —C(O)N(CH3)2, —NCH3C(O)CH3, —NHC(O)CH3, —NCH3S(O)2CH3, —NHS(O)2CH3, —SCH3, —S(O)2CH3, —S(O)2NH2, and —S(O)2N(CH3)2; or R5 and R6, together with the carbon atom to which they are attached, can form a (4- to 6-membered) heterocycloalkyl or (C3-C4) cycloalkyl, wherein the (4- to 6-membered) heterocycloalkyl or (C3-C4) cycloalkyl may be optionally substituted with 1, 2, 3, or 4 of the following groups: —H, —F,
or —OCH3; or R5 and R6 together form an oxo.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), ring A is:
phenyl

### Claim 10 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), each R1 is independently and optionally: —H, —F, —Cl, —Br, —I, —OH, —NO2, —N(CH3)2, —NH2, —CH2OCH3, —CH2N(CH3)2, —CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, —C(O)N(CH3)2, —NCH3C(O)CH3, —NHC(O)CH3, —NCH3S(O)2CH3, —NHS(O)2CH3, —SCH3, —S(O)2CH3, —S(O)2NH2, and —S(O)2N(CH3)2, wherein the (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, (C2-C4) alkenyl, (C2-C4) alkynyl, or (C3-C6) cycloalkyl may be each independently and optionally substituted with 1, 2, 3, or 4 of the following groups: —H, —F, —OH, —CH2OCH3, —CH2N(CH3)2, —OCH3, —N(CH3)2, —NH2, —CN,

### Claim 11 (depends on 10)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 10, wherein in the general formula (1), each R1 is independently: —H, —F, —Cl, —Br, —I, —OH, —NO2, —N(CH3)2, —NH2, —CH2OCH3, —CH2N(CH3)2, —CN, —C(O)N(CH3)2, —NCH3C(O)CH3, —NHC(O)CH3, —NCH3S(O)2CH3, —NHS(O)2CH3, —SCH3, —S(O)2CH3, —S(O)2NH2, —S(O)2N(CH3)2,
—CF3, —CH2CF3,
—OCH3, —OCH2CH3, —OCH(CH3)2,

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), the structural unit

### Claim 14 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), the structural unit

### Claim 15 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), each R2 is independently and optionally: —H, —F, —Cl, —Br, —I, —OH, —N(CH3)2, —NH2, —CN, (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, (C2-C4) alkenyl, (C2-C4) alkynyl, or (C3-C5) cycloalkyl; or two R2 on a same carbon atom, together the carbon atom to which they are attached, can form (4- to 5-membered) heterocycloalkyl or (C3-C5) cycloalkyl, wherein the (4- to 5-membered) heterocycloalkyl or (C3-C5) cycloalkyl may be optionally substituted with 1, 2, 3, or 4 of the following groups: —H, —F,
and —OCH3; or two R2 on a same carbon atom together form an oxo.

### Claim 16 (depends on 15)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 15, wherein in the general formula (1), each R2 is independently and optionally: —H, —F, —Cl, —Br, —I, —OH, —N(CH3)2, —NH2, —CN,
—CF3, —CH2CF3,
OCH3, OCH2CH3, —OCH(CH3)2,

### Claim 17 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), the structural unit

### Claim 18 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), the structural unit

### Claim 19 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein in the general formula (1), the structural unit

### Claim 20 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein the compound has one of the following structures:

### Claim 21 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1, wherein the compound has one of the following structures:

### Claim 22 (depends on 1)

The compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof claim 1, wherein the compound has one of the following structures:

### Claim 23 (depends on 1)

A pharmaceutical composition, comprising a pharmaceutically acceptable excipient or carrier, and the compound or the isomer thereof, the crystalline form thereof, the pharmaceutically acceptable salt thereof, the hydrate thereof, or the solvate thereof according to claim 1 as an active ingredient.

### Claim 24

(canceled)

### Claim 25

(canceled)
